J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Prexasertib data worsen again, and biomarkers are up in the air.
